Senti Biosciences, Inc.
17.82%
6,142,848
1854270
Mar 26, 2026
Apr 16, 2026, 04:50 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Bayer HealthCare LLC | CO | 17.82% | 6,142,848 | 0 | 6,142,848 |
| Bayer US Holding LLC | CO | 17.82% | 6,142,848 | 0 | 6,142,848 |
| Sebastian Guth | Individual | 17.82% | 6,142,848 | 0 | 6,142,848 |
| Priyal Patel | Individual | 17.82% | 6,142,848 | 0 | 6,142,848 |
Disclosure Items (4)
Common Stock, par value $0.0001 per share
Senti Biosciences, Inc.
2 Corporate Drive, South San Francisco, CA, 94080
Bayer HealthCare LLC ("BHC"); Bayer US Holding LLC ("BUSH LLC"); Sebsatian Guth ("Guth") and Priyal Patel ("Patel", together with Guth, the "Managers of BUSH LLC" and collectively, the Managers of BUSH LLC, along with BHC and BUSH LLC, the "Reporting Persons").
BHC - Delaware BUSH LLC - Delaware Guth - Unknown Patel - Unknown
BHC - 17.82% BUSH LLC - 17.82% Guth - 17.82% Patel - 17.82% Each Reporting Person disclaims beneficial ownership of the shares other than those shares which such person owns of record. The percentage of outstanding Issuer Common Stock which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on 31,144,497 shares of Issuer Common Stock reported to be outstanding as of March 19, 2026 on the Issuer's Annual Report on Form 10-K for the period ended December 31, 2025, as filed with the SEC on March 27, 2026.
Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
Exhibit 7.01 - Joint Filing Agreement by and among the Reporting Persons (incorporated by reference to Exhibit 7.01 of the Schedule 13D filed with the SEC on March 17, 2025). Exhibit 7.02 - Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 7.02 of the Schedule 13D filed with the SEC on March 17, 2025). Exhibit 7.02(a) - Power of Attorney regarding filings under the Securities Exchange Act of 1334, as amended. Exhibit 7.03 - Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.04 - Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.05 - Form of Securities Purchase Agreement, dated December 2, 2024, by and among Senti Biosciences, Inc. and the purchasers named therein (incorporated by reference to Exhibit 10.1 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024). Exhibit 7.06 - Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No.001-40440), filed on December 2, 2024).